About this Journal Submit a Manuscript Table of Contents
Prostate Cancer
Volume 2012 (2012), Article ID 580306, 8 pages
http://dx.doi.org/10.1155/2012/580306
Review Article

Androgen Deprivation Therapy Toxicity and Management for Men Receiving Radiation Therapy

Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA

Received 16 November 2012; Accepted 18 December 2012

Academic Editor: J. W. Moul

Copyright © 2012 Matthew E. Johnson and Mark K. Buyyounouski. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. V. Pilepich, K. Winter, M. J. John et al., “Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate,” International Journal of Radiation Oncology Biology Physics, vol. 50, no. 5, pp. 1243–1252, 2001. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Bolla, L. Collette, L. Blank et al., “Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial,” The Lancet, vol. 360, no. 9327, pp. 103–108, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. G. E. Hanks, T. F. Pajak, A. Porter et al., “Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the radiation therapy oncology group protocol 92-02,” Journal of Clinical Oncology, vol. 21, no. 21, pp. 3972–3978, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. A. V. D'Amico, J. Manola, M. Loffredo, A. A. Renshaw, A. DellaCroce, and P. W. Kantoff, “6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial,” The Journal of the American Medical Association, vol. 292, no. 7, pp. 821–827, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Laverdière, A. Nabid, L. D. de Bedoya et al., “The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer,” Journal of Urology, vol. 171, no. 3, pp. 1137–1140, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. M. V. Pilepich, K. Winter, C. A. Lawton et al., “Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma—long-term results of phase III RTOG 85-31,” International Journal of Radiation Oncology Biology Physics, vol. 61, no. 5, pp. 1285–1290, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. T. Granfors, H. Modig, J. E. Damber, and R. Tomic, “Long-term followup of a randomized study of locally advanced prostate cancer treated with combined orchiectomy and external radiotherapy versus radiotherapy alone,” Journal of Urology, vol. 176, no. 2, pp. 544–547, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Bolla, T. M. de Reijke, G. van Tienhoven et al., “Duration of androgen suppression in the treatment of prostate cancer,” The New England Journal of Medicine, vol. 360, no. 24, pp. 2516–2527, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. J. W. Denham, A. Steigler, D. S. Lamb et al., “Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial,” The Lancet Oncology, vol. 12, no. 5, pp. 451–459, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. C. U. Jones, D. Hunt, D. G. McGowan et al., “Radiotherapy and short-term androgen deprivation for localized prostate cancer,” The New England Journal of Medicine, vol. 365, no. 2, pp. 107–118, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. V. B. Shahinian, Y. F. Kuo, J. L. Freeman, E. Orihuela, and J. S. Goodwin, “Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma,” Cancer, vol. 103, no. 8, pp. 1615–1624, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Krahn, K. E. Bremner, G. Tomlinson, J. Luo, P. Ritvo, G. Naglie, et al., “Androgen deprivation therapy in prostate cancer: are rising concerns leading to falling use?” British Journal of Urology International, vol. 108, no. 10, pp. 1588–1596, 2011. View at Publisher · View at Google Scholar
  13. “Lupron depot prescribing information,” http://www.lupron.com/prescribing-information.cfm.
  14. G. N. Levine, A. V. D'Amico, P. Berger et al., “Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American heart association, American cancer society, and American urological association: endorsed by the American society for radiation oncology,” CA: Cancer Journal for Clinicians, vol. 60, no. 3, pp. 194–201, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. W. Shipley, “Initial report of RTOG, 9601, a phase III trial in prostate cancer: effect of anti-androgen therapy (AAT) with bicalutamide during and after radiation therapy (RT) on freedom from progression and incidence of metastatic disease in patients following radical prostatectomy (RP) with pT2-3, N0 disease and elevated PSA levels,” Journal of Clinical Oncology, vol. 29, supplement 7, 2011, abstract no. 1.
  16. M. Roach III, K. Bae, J. Speight et al., “Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610,” Journal of Clinical Oncology, vol. 26, no. 4, pp. 585–591, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Widmark, O. Klepp, A. Solberg et al., “Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial,” The Lancet, vol. 373, no. 9660, pp. 301–308, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Grossmann, E. J. Hamilton, C. Gilfillan, D. Bolton, D. L. Joon, and J. D. Zajac, “Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy,” Medical Journal of Australia, vol. 194, no. 6, pp. 301–306, 2011. View at Scopus
  19. M. R. Smith, J. S. Finkelstein, F. J. McGovern et al., “Changes in body composition during androgen deprivation therapy for prostate cancer,” Journal of Clinical Endocrinology and Metabolism, vol. 87, no. 2, pp. 599–603, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. M. R. Smith, H. Lee, F. McGovem et al., “Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome,” Cancer, vol. 112, no. 10, pp. 2188–2194, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. M. R. Smith, “Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer,” Urology, vol. 63, no. 4, pp. 742–745, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. T. Pischon, H. Boeing, K. Hoffmann et al., “General and abdominal adiposity and risk of death in Europe,” The New England Journal of Medicine, vol. 359, no. 20, pp. 2105–2120, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. U.S. Department of Agriculture and U.S. Department of Health and Human Services, Dietary Guidelines for Americans, 2010, U.S. Government Printing Office, Washington, DC, USA, 7th edition, 2010.
  24. Prospective Studies Collaboration, “Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths,” The Lancet, vol. 370, no. 9602, pp. 1829–1839, 2007. View at Publisher · View at Google Scholar
  25. M. R. Smith, S. B. Malkowicz, F. Chu et al., “Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study,” Journal of Clinical Oncology, vol. 26, no. 11, pp. 1824–1829, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. National Cholesterol Education Program, “Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report,” Circulation, vol. 106, no. 25, pp. 3143–3421, 2002.
  27. M. R. Smith, H. Lee, M. A. Fallon, and D. M. Nathan, “Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer,” Urology, vol. 71, no. 2, pp. 318–322, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. J. C. Smith, S. Bennett, L. M. Evans et al., “The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer,” Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 9, pp. 4261–4267, 2001. View at Publisher · View at Google Scholar · View at Scopus
  29. N. L. Keating, A. J. O'Malley, S. J. Freedland, and M. R. Smith, “Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer,” Journal of the National Cancer Institute, vol. 102, no. 1, pp. 39–46, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. American Diabetes Association, “Standards of medical care in diabetes—2012,” Diabetes Care, vol. 35, supplement 1, pp. S11–S63, 2012.
  31. W. C. Knowler, E. Barrett-Connor, S. E. Fowler et al., “Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin,” The New England Journal of Medicine, vol. 346, no. 6, pp. 393–403, 2002. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Grossmann and J. D. Zajac, “Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated?” Clinical Endocrinology, vol. 74, no. 3, pp. 289–293, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. A. V. D'Amico, J. W. Denham, J. Crook et al., “Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions,” Journal of Clinical Oncology, vol. 25, no. 17, pp. 2420–2425, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. J. A. Efstathiou, K. Bae, W. U. Shipley et al., “Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: Rtog 85-31,” Journal of Clinical Oncology, vol. 27, no. 1, pp. 92–99, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Bolla, G. van Tienhoven, P. Warde et al., “External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study,” The Lancet Oncology, vol. 11, no. 11, pp. 1066–1073, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. P. L. Nguyen, Y. Je, F. A. B. Schutz et al., “Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials,” The Journal of the American Medical Association, vol. 306, no. 21, pp. 2359–2366, 2011. View at Publisher · View at Google Scholar
  37. A. V. Chobanian, G. L. Bakris, H. R. Black et al., “The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report,” The Journal of the American Medical Association, vol. 289, no. 19, pp. 2560–2572, 2003. View at Publisher · View at Google Scholar · View at Scopus
  38. D. A. Galvão, D. R. Taaffe, N. Spry, D. Joseph, D. Turner, and R. U. Newton, “Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: a comprehensive cross-sectional investigation,” Prostate Cancer and Prostatic Diseases, vol. 12, no. 2, pp. 198–203, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. R. J. Segal, R. D. Reid, K. S. Courneya et al., “Resistance exercise in men receiving androgen deprivation therapy for prostate cancer,” Journal of Clinical Oncology, vol. 21, no. 9, pp. 1653–1659, 2003. View at Publisher · View at Google Scholar · View at Scopus
  40. D. A. Galvão, D. R. Taaffe, N. Spry, D. Joseph, and R. U. Newton, “Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial,” Journal of Clinical Oncology, vol. 28, no. 2, pp. 340–347, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. A. Berruti, L. Dogliotti, C. Terrone et al., “Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy,” Journal of Urology, vol. 167, no. 6, pp. 2361–2367, 2002. View at Scopus
  42. E. J. Hamilton, A. Ghasem-Zadeh, E. Gianatti et al., “Structural decay of bone microarchitecture in men with prostate cancer treated with androgen deprivation therapy,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 12, pp. E456–E463, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. M. R. Smith, F. J. McGovern, A. L. Zietman et al., “Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer,” The New England Journal of Medicine, vol. 345, no. 13, pp. 948–955, 2001. View at Publisher · View at Google Scholar · View at Scopus
  44. M. R. Smith, S. P. Boyce, E. Moyneur, M. S. Duh, M. K. Raut, and J. Brandman, “Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer,” Journal of Urology, vol. 175, no. 1, pp. 136–139, 2006. View at Publisher · View at Google Scholar · View at Scopus
  45. V. B. Shahinian, Y. F. Kuo, J. L. Freeman, and J. S. Goodwin, “Risk of fracture after androgen deprivation for prostate cancer,” The New England Journal of Medicine, vol. 352, no. 2, pp. 154–164, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. J. Morote, J. P. Morin, A. Orsola et al., “Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer,” Urology, vol. 69, no. 3, pp. 500–504, 2007. View at Publisher · View at Google Scholar · View at Scopus
  47. P. R. Ebeling, “Osteoporosis in men,” The New England Journal of Medicine, vol. 358, no. 14, pp. 1474–1482, 2008. View at Publisher · View at Google Scholar · View at Scopus
  48. T. H. Diamond, J. Winters, A. Smith et al., “The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study,” Cancer, vol. 92, no. 6, pp. 1444–1450, 2001. View at Publisher · View at Google Scholar
  49. S. L. Greenspan, J. B. Nelson, D. L. Trump, and N. M. Resnick, “Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial,” Annals of Internal Medicine, vol. 146, no. 6, pp. 416–424, 2007. View at Scopus
  50. M. D. Michaelson, D. S. Kaufman, H. Lee et al., “Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer,” Journal of Clinical Oncology, vol. 25, no. 9, pp. 1038–1042, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. M. R. Smith, J. Eastham, D. M. Gleason, D. Shasha, S. Tchekmedyian, and N. Zinner, “Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer,” Journal of Urology, vol. 169, no. 6, pp. 2008–2012, 2003. View at Publisher · View at Google Scholar · View at Scopus
  52. M. R. Smith, B. Egerdie, N. H. Toriz et al., “Denosumab in men receiving androgen-deprivation therapy for prostate cancer,” The New England Journal of Medicine, vol. 361, no. 8, pp. 745–755, 2009. View at Publisher · View at Google Scholar · View at Scopus
  53. “Prolia prescribing information,” http://pi.amgen.com/united_states/prolia/prolia_pi.pdf.
  54. “Xgeva prescribing information,” http://pi.amgen.com/united_states/xgeva/xgeva_pi.pdf.
  55. M. R. Smith, M. A. Fallon, H. Lee, and J. S. Finkelstein, “Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 8, pp. 3841–3846, 2004. View at Publisher · View at Google Scholar · View at Scopus
  56. M. R. Smith, R. A. Morton, K. G. Barnette et al., “Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer,” Journal of Urology, vol. 184, no. 4, pp. 1316–1321, 2010. View at Publisher · View at Google Scholar
  57. National Osteoporosis Foundation, Clinician's Guide to Prevention and Treatment of Osteoporosis, 2010, http://www.nof.org/professionals/clinical-guidelines.
  58. F. Saad, J. D. Adachi, J. P. Brown et al., “Cancer treatment-induced bone loss in breast and prostate cancer,” Journal of Clinical Oncology, vol. 26, no. 33, pp. 5465–5476, 2008. View at Publisher · View at Google Scholar · View at Scopus
  59. N. B. Watts, E. M. Lewiecki, P. D. Miller, and S. Baim, “National osteoporosis foundation 2008 clinician's guide to prevention and treatment of osteoporosis and the world health organization fracture risk assessment tool (FRAX): what they mean to the bone densitometrist and bone technologist,” Journal of Clinical Densitometry, vol. 11, no. 4, pp. 473–477, 2008. View at Publisher · View at Google Scholar · View at Scopus
  60. J. Irani, L. Salomon, R. Oba, P. Bouchard, and N. Mottet, “Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial,” The Lancet Oncology, vol. 11, no. 2, pp. 147–154, 2010. View at Publisher · View at Google Scholar · View at Scopus
  61. M. D. Michaelson, S. E. Cotter, P. C. Gargollo, A. L. Zietman, D. M. Dahl, and M. R. Smith, “Management of complications of prostate cancer treatment,” CA: Cancer Journal for Clinicians, vol. 58, no. 4, pp. 196–213, 2008. View at Publisher · View at Google Scholar · View at Scopus
  62. J. Frisk, A. C. Spetz, H. Hjertberg, B. Petersson, and M. Hammar, “Two modes of acupuncture as a treatment for hot flushes in men with prostate cancer—a prospective multicenter study with long-term follow-up,” European Urology, vol. 55, no. 1, pp. 156–163, 2009. View at Publisher · View at Google Scholar · View at Scopus
  63. G. S. Gerber, G. P. Zagaja, P. S. Ray, and D. B. Rukstalis, “Transdermal estrogen in the treatment of hot flushes in men with prostate cancer,” Urology, vol. 55, no. 1, pp. 97–101, 2000. View at Publisher · View at Google Scholar · View at Scopus
  64. C. L. Loprinzi, J. C. Michalak, S. K. Quella et al., “Megestrol acetate for the prevention of hot flashes,” The New England Journal of Medicine, vol. 331, no. 6, pp. 347–352, 1994. View at Publisher · View at Google Scholar · View at Scopus
  65. N. Sharifi, J. L. Gulley, and W. L. Dahut, “Androgen deprivation therapy for prostate cancer,” The Journal of the American Medical Association, vol. 294, no. 2, pp. 238–244, 2005. View at Publisher · View at Google Scholar · View at Scopus
  66. E. Salminen, R. Portin, J. Korpela et al., “Androgen deprivation and cognition in prostate cancer,” British Journal of Cancer, vol. 89, no. 6, pp. 971–976, 2003. View at Publisher · View at Google Scholar · View at Scopus
  67. S. Alibhai, “Impact of 12 months of androgen deprivation therapy (ADT) on cognitive function in men with nonmetaastatic prostate cancer (PC): a matched cohort study,” Journal of Clinical Oncology, abstract no. 9027, 2010.
  68. V. B. Shahinian, Y. F. Kuo, J. L. Freeman, and J. S. Goodwin, “Risk of the “androgen deprivation syndrome” in men receiving androgen deprivation for prostate cancer,” Archives of Internal Medicine, vol. 166, no. 4, pp. 465–471, 2006. View at Publisher · View at Google Scholar · View at Scopus
  69. A. L. Potosky, K. Knopf, L. X. Clegg et al., “Quality-of-life outcomes after primary androgen deprivation therapy: results from the prostate cancer outcomes study,” Journal of Clinical Oncology, vol. 19, no. 17, pp. 3750–3757, 2001. View at Scopus
  70. P. E. Teloken, M. Ohebshalom, N. Mohideen, and J. P. Mulhall, “Analysis of the impact of androgen deprivation therapy on sildenafil citrate response following radiation therapy for prostate cancer,” Journal of Urology, vol. 178, no. 6, pp. 2521–2525, 2007. View at Publisher · View at Google Scholar · View at Scopus
  71. G. Di Lorenzo, S. Perdoná, S. de Placido et al., “Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: the role of tamoxifen and radiotherapy,” Journal of Urology, vol. 174, no. 6, pp. 2197–2203, 2005. View at Publisher · View at Google Scholar · View at Scopus
  72. S. Perdonà, R. Autorino, S. de Placido et al., “Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial,” The Lancet Oncology, vol. 6, no. 5, pp. 295–300, 2005. View at Publisher · View at Google Scholar · View at Scopus
  73. S. Cook and A. Rodríguez-Antunez, “Pre-estrogen irradiation of the breast to prevent gynecomastia,” The American Journal of Roentgenology, Radium Therapy, and Nuclear Medicine, vol. 117, no. 3, pp. 662–663, 1973. View at Scopus
  74. D. Fass, A. Steinfeld, J. Brown, and A. Tessler, “Radiotherapeutic prophylaxis of estrogen-induced gynecomastia: a study of late sequela,” International Journal of Radiation Oncology Biology Physics, vol. 12, no. 3, pp. 407–408, 1986. View at Scopus
  75. L. Gunderson and J. Tepper, Clinical Radiation Oncology, 3rd edition, 2011.
  76. F. Boccardo, A. Rubagotti, M. Battaglia et al., “Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer,” Journal of Clinical Oncology, vol. 23, no. 4, pp. 808–815, 2005. View at Publisher · View at Google Scholar · View at Scopus